Shares in biopharmaceutical company Clinuvel have recently benefited from positive preliminary results in its phase three porphyria trial.
The trial aims to treat people with erythropoietic protoporphyria, a condition where patients are absolutely intolerant to visible and ultraviolet light.
Loading...
Joyce Moullakis wrote on banking and finance, specialising in Investment Banking, Private Equity, Financial Services. Connect with Joyce on Twitter. Email Joyce at jmoullakis@afr.com.au
